Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

13.74 +0.14 (+1.03%)
Streaming Delayed Price Updated: 12:38 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday. 
Via Benzinga
Instacart, ARS Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Analyst Expectations for ARS Pharmaceuticals's Future
Via Benzinga
FDA Issues Some Concerns Regarding ARS Pharma's Investigational Allergy Treatment
The FDA released  
Via Benzinga
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
Additional Time Needed for Labeling and Post-Marketing Requirements Discussions; PDUFA Date Set for September 19, 2023 
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Nasdaq Down 100 Points; Crude Oil Drops Over 1%
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Friday. The Dow traded down 0.43% to 33,164.71 while the NASDAQ fell 0.82% to 12,227.60. The... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Turns Lower; Getaround Shares Jump
U.S. stocks traded lower midway through trading, with the Dow Jones turning lower on Friday. The Dow traded down 0.25% to 33,226.13 while the NASDAQ fell 0.45% to 12,271.22. The S&P 500, also fell,... 
Via Benzinga
Arlo Technologies, Array Technologies, AirSculpt Technologies And Other Big Stocks Moving Higher On Friday
U.S. stocks traded slightly lower, with the Dow Jones dropping around 15 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16,... 
Via Benzinga
Why ARS Pharmaceuticals Stock Is Soaring Today
The FDA's Pulmonary-Allergy Drug Advisory Committee voted 16-6 in favor of ARS Pharmaceuticals Inc's (NASDAQ: SPRY) neffy in treating severe allergic reactions for adults (and 16-5 for  
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why MBIA Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Unique Fabricating, Inc. (NYSE: UFAB) climbed 205% to $0.55 after gaining around 4% on Tuesday. 
Via Benzinga
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ARS Pharmaceuticals, Inc. (SPRY) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.